Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2025-04-04 00:00:00 ET · period of report 2025-04-03 · accession 0001689375-25-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-04 | 2025-04-03 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +11.1K | 120.7K | +10% | +$23.4K |
| D | 2025-04-04 | 2025-04-03 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $0.00 | -11.1K | 20.0K | -36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-03 | M | A | 11,134 | $2.10 | 120,670 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-04-03 | M | D | 11,134 | $0.00 | 20,023 | D | $2.10 · — to 2030-11-10 | 11,134 Common Stock | (F1) The shares subject to this option fully vested on November 16, 2024. |